Survey: Would You Still Recommend Drug-Eluting Stents?
Drug-eluting stents essentially eliminated short-term restenosis as a complication of coronary angioplasty, but suddenly the coated devices have come under a cloud for possible late term risks. This Medpage Today survey asks your opinion about the future use of drug-eluting stents. Additional Stent Coverage from ESC: Meta-Analyses Find Increased Death and MI with Cypher Stent Real World Trial Confirms Drug-Eluting Stents Better in Small Vessels Investigational Drug-Eluting Stent Superior to Taxus Drug-Eluting Stent Debate Develops Fever Pitch
Drug-eluting stents essentially eliminated short-term restenosis as a complication of coronary angioplasty, but suddenly the coated devices have come under a cloud for possible late-term risks.
Cardiologists attending the European Society of Cardiology/World Congress of Cardiology in Barcelona last week were shocked by meta-analyses data that raised serious questions about the long-term safety of the devices.
This Medpage Today survey asks for your opinion about whether you still have confidence in the elective use of drug-eluting stents.
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.
